MGO One Seven LLC Reduces Stock Holdings in DexCom, Inc. $DXCM

MGO One Seven LLC trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 3.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,100 shares of the medical device company’s stock after selling 167 shares during the period. MGO One Seven LLC’s holdings in DexCom were worth $358,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Nuveen LLC purchased a new position in DexCom in the first quarter worth about $554,893,000. Jennison Associates LLC lifted its position in shares of DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after buying an additional 2,879,489 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock valued at $218,175,000 after buying an additional 2,015,971 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of DexCom by 2,371.4% during the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock valued at $136,220,000 after buying an additional 1,914,019 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after buying an additional 1,868,241 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DXCM. William Blair raised DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Barclays lifted their price objective on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. Piper Sandler lifted their price objective on DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, July 31st. Mizuho lifted their price objective on DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $97.00.

DexCom Stock Up 0.4%

NASDAQ DXCM opened at $66.60 on Friday. The stock’s 50 day moving average is $73.35 and its 200 day moving average is $77.58. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The stock has a market cap of $26.12 billion, a PE ratio of 46.25, a P/E/G ratio of 1.40 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the company posted $0.43 EPS. The company’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. The trade was a 1.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.